Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 657 articles:
HTML format



Single Articles


    May 2020
  1. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    PubMed     Abstract available


  2. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


  3. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    PubMed     Abstract available


  4. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    PubMed     Abstract available


  5. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    PubMed     Abstract available


  6. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    PubMed     Abstract available


  7. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    PubMed     Abstract available


  8. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    PubMed     Abstract available


    April 2020
  9. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    PubMed     Abstract available


  10. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed     Abstract available


  11. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    PubMed     Abstract available


  12. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    PubMed     Abstract available


  13. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed     Abstract available


  14. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed     Abstract available


  15. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed     Abstract available


    March 2020
  16. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    PubMed     Abstract available


  17. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    PubMed     Abstract available


  18. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    PubMed     Abstract available


  19. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available


  20. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available


  21. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available


  22. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available


  23. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available


  24. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available


  25. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available


  26. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available


  27. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available


  28. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available


  29. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available


    February 2020
  30. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
    Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
    Mult Scler. 2020 Feb 27:1352458520907900. doi: 10.1177/1352458520907900.
    PubMed     Abstract available


  31. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available


  32. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available


  33. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available


  34. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available


  35. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available


  36. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available


  37. SERRA A, Petzold A
    Can stability of visual fixation be a measure for disability in multiple sclerosis?
    Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
    PubMed    


  38. SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
    Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
    PubMed     Abstract available


  39. BSTEH G, Berger T
    Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
    Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
    PubMed    


  40. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available


  41. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available


  42. BOUVET L, Chassard D
    Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
    Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
    PubMed    


  43. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available


  44. ABSINTA M, Ontaneda D
    Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
    Mult Scler. 2020;26:135-136.
    PubMed    


    January 2020
  45. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available


  46. PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
    A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
    Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
    PubMed     Abstract available


  47. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available


  48. CHITNIS T, Prat A
    A roadmap to precision medicine for multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
    PubMed     Abstract available


  49. BOSE G, Freedman MS
    Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
    Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
    PubMed     Abstract available


  50. MYCKO MP, Baranzini SE
    microRNA and exosome profiling in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
    PubMed     Abstract available


  51. VOSKUHL RR
    The effect of sex on multiple sclerosis risk and disease progression.
    Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
    PubMed     Abstract available


  52. PATSOPOULOS NA, De Jager PL
    Genetic and gene expression signatures in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
    PubMed     Abstract available


  53. BHARGAVA P, Anthony D
    Metabolomics in multiple sclerosis disease course and progression.
    Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
    PubMed     Abstract available


  54. KISTER I, Kantarci OH
    Multiple Sclerosis Severity Score: Concept and applications.
    Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
    PubMed     Abstract available


  55. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available


  56. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available


  57. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available


  58. MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
    World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
    PubMed     Abstract available


  59. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available


    December 2019
  60. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available


  61. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available


  62. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available


  63. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available


  64. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available


  65. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available


  66. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available


  67. HARDY TA
    Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
    Mult Scler. 2019;25:1945-1946.
    PubMed    


    November 2019
  68. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available


  69. COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
    Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
    Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
    PubMed     Abstract available


  70. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available


  71. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available


  72. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available


  73. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available


  74. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available


  75. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available


  76. ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
    7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
    PubMed     Abstract available


  77. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available


  78. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available


  79. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available


  80. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available


  81. MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
    The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
    PubMed     Abstract available


  82. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available


  83. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available


  84. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available


  85. MOSTERT JP, De Keyser J
    Response to Grech et al.: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1820-1821.
    PubMed    


  86. GRECH LB, Butler E, Stuckey S, Hester R, et al
    Letter to the editor: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1819-1820.
    PubMed    


    October 2019
  87. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available


  88. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available


  89. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available


  90. CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
    Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
    Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
    PubMed     Abstract available


  91. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available


  92. WOJCIK CM, Beier M, Costello K, DeLuca J, et al
    Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
    Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
    PubMed     Abstract available


  93. CHITNIS T
    Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
    Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
    PubMed    


  94. MYHR KM, Torkildsen O
    Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
    Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
    PubMed    


  95. LEPPERT D, Kuhle J
    Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
    Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
    PubMed    


  96. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available


  97. BILODEAU PA, Kumar V, Rodriguez AE, Li CT, et al
    MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
    Mult Scler. 2019 Oct 17:1352458519872895. doi: 10.1177/1352458519872895.
    PubMed     Abstract available


  98. MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
    Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
    Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
    PubMed     Abstract available


  99. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available


  100. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available


  101. BIANCHI A, Ciccarelli O
    Daclizumab-induced encephalitis in multiple sclerosis.
    Mult Scler. 2019;25:1557-1559.
    PubMed    


  102. IGHANI M, Jonas S, Izbudak I, Choi S, et al
    No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
    PubMed     Abstract available


  103. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available


  104. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available


  105. MACARON G, Ontaneda D
    Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Mult Scler. 2019;25:1550-1552.
    PubMed    


  106. BERGER JR
    PML with dimethyl fumarate-No role for natalizumab?
    Mult Scler. 2019;25:1686-1687.
    PubMed    


    September 2019
  107. PALOTAI M, Guttmann CR
    Brain anatomical correlates of fatigue in multiple sclerosis.
    Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
    PubMed     Abstract available


  108. MAGGI P, Absinta M, Sati P, Perrotta G, et al
    The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
    Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
    PubMed     Abstract available


  109. MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
    Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
    Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
    PubMed     Abstract available


  110. VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
    Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
    Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
    PubMed     Abstract available


  111. BRANDSTADTER R, Katz Sand I, Sumowski JF
    Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
    Mult Scler. 2019;25:1372-1378.
    PubMed     Abstract available


  112. WEBER E, Goverover Y, DeLuca J
    Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
    Mult Scler. 2019;25:1412-1419.
    PubMed     Abstract available


    August 2019
  113. PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
    Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
    Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
    PubMed     Abstract available


  114. FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
    Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
    PubMed     Abstract available


  115. PISA M, Ratti F, Vabanesi M, Radaelli M, et al
    Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
    Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
    PubMed     Abstract available


  116. SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
    Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
    Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
    PubMed     Abstract available


  117. KILLESTEIN J, van Oosten B
    Emerging safety issues in alemtuzumab-treated MS patients.
    Mult Scler. 2019;25:1206-1208.
    PubMed    


  118. HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
    Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
    Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
    PubMed     Abstract available


  119. MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
    Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
    Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
    PubMed     Abstract available


  120. BOVE R, Rankin K, Lin C, Zhao C, et al
    Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
    Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
    PubMed     Abstract available


  121. BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
    The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
    Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
    PubMed     Abstract available


    July 2019
  122. SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
    Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
    Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
    PubMed     Abstract available


  123. SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
    Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
    Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
    PubMed     Abstract available


  124. CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
    Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
    Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
    PubMed     Abstract available


  125. LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
    Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
    PubMed     Abstract available


  126. PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
    Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
    PubMed     Abstract available


  127. CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
    How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
    Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
    PubMed     Abstract available


  128. BRIGGS FB, Hill E
    Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
    Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
    PubMed     Abstract available


  129. HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
    Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
    Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
    PubMed     Abstract available


  130. CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
    Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
    Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
    PubMed     Abstract available


  131. WARNKE C, Hartung HP
    Challenging a concept: Pulsed treatment regimen-No risk of PML?
    Mult Scler. 2019;25:1076-1078.
    PubMed    


  132. GEREVINI S, Capra R, Bertoli D, Sottini A, et al
    Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2019;25:1196-1201.
    PubMed     Abstract available


  133. PREZIOSA P, Rocca MA, Filippi M
    PET is necessary to make the next step forward in understanding MS pathophysiology - No.
    Mult Scler. 2019;25:1088-1090.
    PubMed    


  134. BODINI B, Stankoff B
    PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
    Mult Scler. 2019;25:1086-1087.
    PubMed    


  135. KUMAR N, Abboud H
    Iatrogenic CNS demyelination in the era of modern biologics.
    Mult Scler. 2019;25:1079-1085.
    PubMed     Abstract available


  136. COMBES B, Kerbrat A, Ferre JC, Callot V, et al
    Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
    Mult Scler. 2019;25:1113-1123.
    PubMed     Abstract available


  137. BICHUETTI DB, Perin MMM, Souza NA, Oliveira EML, et al
    Treating neuromyelitis optica with azathioprine: 20-year clinical practice.
    Mult Scler. 2019;25:1150-1161.
    PubMed     Abstract available


  138. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    PubMed    


    June 2019
  139. DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
    Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
    Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
    PubMed     Abstract available


  140. INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
    Rituximab treatment for multiple sclerosis.
    Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
    PubMed     Abstract available


  141. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available


  142. LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
    Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
    Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
    PubMed     Abstract available


  143. PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
    A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
    Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
    PubMed     Abstract available


  144. MARCK CH, das Nair R, Grech LB, Borland R, et al
    Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
    Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
    PubMed     Abstract available


  145. FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
    Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
    Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
    PubMed     Abstract available


  146. CHATAWAY J, Weir CJ, Fox RJ
    The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
    Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
    PubMed    


  147. CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
    Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
    PubMed     Abstract available


  148. SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
    Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
    Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
    PubMed     Abstract available


  149. GABR RE, Coronado I, Robinson M, Sujit SJ, et al
    Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
    Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
    PubMed     Abstract available


  150. KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
    Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
    Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
    PubMed     Abstract available


  151. BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
    Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
    Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
    PubMed     Abstract available


  152. MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
    Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
    PubMed     Abstract available


  153. STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
    Obesity worsens central inflammation and disability in multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
    PubMed     Abstract available


  154. MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
    Response to Vilarino-Guell et al.
    Mult Scler. 2019;25:1013-1015.
    PubMed    


  155. SCALFARI A
    MS progression is predominantly driven by age-related mechanisms - YES.
    Mult Scler. 2019;25:902-904.
    PubMed    


  156. MCGINLEY M, Ontaneda D
    MS progression is predominantly driven by age-related mechanisms - NO.
    Mult Scler. 2019;25:904-906.
    PubMed    


  157. ROCCA MA, Savoldi F, Valsasina P, Radaelli M, et al
    Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders.
    Mult Scler. 2019;25:968-979.
    PubMed     Abstract available


  158. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    PubMed    


    May 2019
  159. SCARPAZZA C, Signori A, Cosottini M, Sormani MP, et al
    Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
    Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162.
    PubMed     Abstract available


  160. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed    


  161. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Abstract available


  162. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Abstract available


  163. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Abstract available


  164. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Abstract available


  165. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Abstract available


  166. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed    


  167. AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
    Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
    Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
    PubMed     Abstract available


  168. MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
    Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
    Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
    PubMed     Abstract available


  169. PUGLIATTI M
    Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
    Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
    PubMed    


  170. KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
    Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
    PubMed     Abstract available


  171. CONTE A, Gianni C, Belvisi D, Cortese A, et al
    Deep grey matter involvement and altered sensory gating in multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
    PubMed     Abstract available


  172. FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
    Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
    PubMed     Abstract available


  173. MOSS BP, Cohen JA
    The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
    PubMed     Abstract available


  174. TUR C, Grussu F, Prados F, Charalambous T, et al
    A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
    PubMed     Abstract available


  175. FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
    The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
    Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
    PubMed     Abstract available


  176. FAZEKAS F
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
    Mult Scler. 2019;25:770-771.
    PubMed    


  177. SOLOMON AJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
    Mult Scler. 2019;25:766-768.
    PubMed    


  178. BROWNLEE WJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
    Mult Scler. 2019;25:768-770.
    PubMed    


  179. TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
    Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Mult Scler. 2019;25:876-879.
    PubMed     Abstract available


  180. ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
    eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
    Mult Scler. 2019;25:856-866.
    PubMed     Abstract available


  181. GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
    Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Mult Scler. 2019;25:837-847.
    PubMed     Abstract available


  182. DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
    Efficacy of rituximab in refractory RRMS.
    Mult Scler. 2019;25:828-836.
    PubMed     Abstract available


    April 2019
  183. PHELPS R, Winston JA, Wynn D, Habek M, et al
    Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
    PubMed     Abstract available


  184. BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
    Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
    Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
    PubMed     Abstract available


  185. VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
    Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
    PubMed     Abstract available


  186. BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
    Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
    Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
    PubMed     Abstract available


  187. BANWELL B
    Are children with multiple sclerosis really "old" adults.
    Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
    PubMed    


  188. BARTELS F, Nobis K, Cooper G, Wendel E, et al
    Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
    Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
    PubMed     Abstract available


  189. LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
    Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
    Mult Scler. 2019;25:591-600.
    PubMed     Abstract available


  190. BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
    Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Mult Scler. 2019;25:565-573.
    PubMed     Abstract available


  191. HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
    Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Mult Scler. 2019;25:585-590.
    PubMed     Abstract available


  192. ZELEK WM, Watkins LM, Howell OW, Evans R, et al
    Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
    Mult Scler. 2019;25:523-531.
    PubMed     Abstract available


  193. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    PubMed    


  194. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    PubMed    


  195. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    PubMed     Abstract available


  196. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    PubMed     Abstract available


    March 2019
  197. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
    PubMed     Abstract available


  198. BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
    Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
    PubMed     Abstract available


  199. BAGNATO F, Franco G, Ye F, Fan R, et al
    Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
    PubMed     Abstract available


  200. D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
    Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
    Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
    PubMed     Abstract available


  201. RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
    Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
    PubMed    


  202. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed     Abstract available


  203. STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
    Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
    Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
    PubMed     Abstract available


  204. BARANZINI SE
    Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
    Mult Scler. 2019;25:336-337.
    PubMed     Abstract available


  205. CAMARA-LEMARROY CR, Burton JM
    Area postrema syndrome: A short history of a pearl in demyelinating diseases.
    Mult Scler. 2019;25:325-329.
    PubMed     Abstract available


  206. WATTJES MP, Killestein J
    Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
    Mult Scler. 2019;25:331-333.
    PubMed    


  207. ABSINTA M, Reich DS
    Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
    Mult Scler. 2019;25:330-331.
    PubMed    


  208. DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
    Prediction of natalizumab anti-drug antibodies persistency.
    Mult Scler. 2019;25:392-398.
    PubMed     Abstract available


  209. ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
    Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
    Mult Scler. 2019;25:372-381.
    PubMed     Abstract available


  210. AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
    Characteristics of morphologic macular abnormalities in neuroimmunology practice.
    Mult Scler. 2019;25:361-371.
    PubMed     Abstract available


    February 2019
  211. PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
    Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
    Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
    PubMed     Abstract available


  212. URRU SA, Antonelli A, Sechi GM
    Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
    Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
    PubMed     Abstract available


  213. PORTACCIO E, Amato MP
    Breastfeeding and post-partum relapses in multiple sclerosis patients.
    Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
    PubMed     Abstract available


  214. CUKER A, Bass AD, Nadj C, Agius MA, et al
    Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
    PubMed     Abstract available


  215. JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
    Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
    PubMed     Abstract available


  216. SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
    Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
    PubMed     Abstract available


  217. CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
    Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
    Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
    PubMed    


  218. LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
    The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
    PubMed     Abstract available


  219. NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
    Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
    PubMed     Abstract available


  220. RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
    Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
    Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
    PubMed     Abstract available


  221. PLANCHE V, Su JH, Mournet S, Saranathan M, et al
    White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
    PubMed     Abstract available


  222. CHARD DT
    Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
    Mult Scler. 2019;25:298-299.
    PubMed     Abstract available


  223. BARANZINI SE
    Insights into microbiome research 5: Mapping is first but function must come next.
    Mult Scler. 2019;25:193-195.
    PubMed     Abstract available


  224. HELLWIG K
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
    Mult Scler. 2019;25:189-190.
    PubMed    


  225. ALVAREZ E, Mowry EM
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
    Mult Scler. 2019;25:187-188.
    PubMed    


  226. BOVE R
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
    Mult Scler. 2019;25:190-192.
    PubMed    


  227. HEDSTROM AK
    Smoking and its interaction with genetics in MS etiology.
    Mult Scler. 2019;25:180-186.
    PubMed     Abstract available


  228. BSTEH G, Hegen H, Ladstatter F, Berek K, et al
    Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
    Mult Scler. 2019;25:267-274.
    PubMed     Abstract available


  229. BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
    Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2019;25:217-223.
    PubMed     Abstract available


    January 2019
  230. SECHI E, Flanagan EP
    Area postrema syndrome in autoimmune GFAP astrocytopathy.
    Mult Scler. 2019 Jan 21:1352458519826489. doi: 10.1177/1352458519826489.
    PubMed    


  231. STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
    Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
    Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
    PubMed     Abstract available


  232. CORDANI C, Meani A, Esposito F, Valsasina P, et al
    Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
    Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
    PubMed     Abstract available


  233. VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
    The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
    Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
    PubMed     Abstract available


  234. VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
    Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
    Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
    PubMed     Abstract available


  235. BARIN L, Kamm CP, Salmen A, Dressel H, et al
    How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
    Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
    PubMed     Abstract available


  236. MARRODAN M, Alessandro L, Farez MF, Correale J, et al
    The role of infections in multiple sclerosis.
    Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
    PubMed     Abstract available


  237. PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
    Structural connectivity in multiple sclerosis and modeling of disconnection.
    Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
    PubMed     Abstract available


  238. JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
    Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
    Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
    PubMed     Abstract available


  239. FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
    Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
    Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
    PubMed     Abstract available


  240. BARANZINI SE
    Insights into microbiome research 4: The computational analysis.
    Mult Scler. 2019;25:21-22.
    PubMed     Abstract available


  241. THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
    MSJ 2019 - Editorial comment.
    Mult Scler. 2019;25:4-5.
    PubMed    


  242. SA M, Thornton R, Chong WK, Kaliakatsos M, et al
    Paediatric MOG antibody-associated ADEM with complex movement disorder: A case report.
    Mult Scler. 2019;25:125-128.
    PubMed     Abstract available


  243. BREZA M, Smyrni N, Koutsis G, Anagnostou E, et al
    Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report.
    Mult Scler. 2019;25:122-125.
    PubMed     Abstract available


  244. PITT D, Ponath G
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
    Mult Scler. 2019;25:15-17.
    PubMed    


  245. KERLERO DE ROSBO N
    Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
    Mult Scler. 2019;25:17-19.
    PubMed    


  246. VIJAYASINGHAM L, Viswanathan S
    A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
    Mult Scler. 2019;25:130-131.
    PubMed    


  247. PATEL VP, Feinstein A
    The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
    Mult Scler. 2019;25:118-121.
    PubMed     Abstract available


  248. MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
    Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mult Scler. 2019;25:63-71.
    PubMed     Abstract available


  249. MARIGNIER R
    Unusual presentations of MOG antibody-associated central nervous system demyelination: Expanding the spectrum.
    Mult Scler. 2019;25:128-129.
    PubMed    


  250. QUINTANA FJ
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
    Mult Scler. 2019;25:19-20.
    PubMed    


    December 2018
  251. HOGEL H, Rissanen E, Barro C, Matilainen M, et al
    Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
    PubMed     Abstract available


  252. SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
    Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
    Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
    PubMed     Abstract available


  253. ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
    Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
    PubMed     Abstract available


  254. MATTHEWS L
    Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
    Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
    PubMed    


  255. PATEL KR, Karaa A, Mateen FJ
    Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
    Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
    PubMed     Abstract available


  256. POURCHER V, Todesco E, Dubois C, Pallier C, et al
    False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
    Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
    PubMed    


  257. BSTEH G, Algrang L, Hegen H, Auer M, et al
    Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
    PubMed     Abstract available


  258. VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
    Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
    PubMed     Abstract available


    November 2018
  259. CHIEN C, Scheel M, Schmitz-Hubsch T, Borisow N, et al
    Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Mult Scler. 2018 Nov 26:1352458518815596. doi: 10.1177/1352458518815596.
    PubMed     Abstract available


  260. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
    Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
    PubMed     Abstract available


  261. WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
    Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
    Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
    PubMed     Abstract available


  262. WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
    Month-of-birth-effect in multiple sclerosis in Austria.
    Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
    PubMed     Abstract available


  263. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed    


  264. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed    


  265. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed    


  266. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Abstract available


  267. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Abstract available


  268. LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
    Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
    Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
    PubMed     Abstract available


  269. LAMERS I, Feys P
    Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
    Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
    PubMed    


  270. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
    PubMed     Abstract available


  271. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Abstract available


  272. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Abstract available


  273. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Abstract available


  274. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Abstract available


    October 2018
  275. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed    


  276. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
    De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
    PubMed     Abstract available


  277. DOBSON R
    Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
    Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
    PubMed    


  278. FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
    Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
    Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
    PubMed     Abstract available


  279. AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
    Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
    PubMed     Abstract available


  280. SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
    The Multiple Sclerosis Care Unit.
    Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
    PubMed     Abstract available


  281. ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
    Diet quality and risk of multiple sclerosis in two cohorts of US women.
    Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
    PubMed     Abstract available


  282. STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
    Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
    PubMed     Abstract available


  283. BURROWS DJ, McGown A, Jain SA, De Felice M, et al
    Animal models of multiple sclerosis: From rodents to zebrafish.
    Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
    PubMed     Abstract available


  284. DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
    Inclusion criteria used in trials of people with progressive multiple sclerosis.
    Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
    PubMed    


  285. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Abstract available


  286. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Abstract available


  287. PFEUFFER S
    Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
    Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
    PubMed    


  288. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Abstract available


  289. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Abstract available


  290. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed    


  291. KREMER D, Akkermann R, Kury P, Dutta R, et al
    Current advancements in promoting remyelination in multiple sclerosis.
    Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
    PubMed     Abstract available


  292. TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
    PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
    Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
    PubMed     Abstract available


    September 2018
  293. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Abstract available


  294. MIN M, Spelman T, Lugaresi A, Boz C, et al
    Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
    PubMed     Abstract available


  295. LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
    e-Health and multiple sclerosis: An update.
    Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
    PubMed     Abstract available


  296. ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
    Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
    Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
    PubMed     Abstract available


  297. ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
    Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
    Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
    PubMed     Abstract available


  298. O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
    Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
    PubMed     Abstract available


  299. BENJAMIN LA
    A tale of two demyelinating diseases and Zika virus.
    Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
    PubMed    


    August 2018
  300. VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
    gMS-Classifier1 does not predict disability progression in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
    PubMed    


  301. VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
    Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
    PubMed     Abstract available


  302. O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
    Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
    Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
    PubMed     Abstract available


  303. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Abstract available


  304. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Abstract available


  305. SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
    Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
    Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
    PubMed     Abstract available


  306. ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
    Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
    Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
    PubMed     Abstract available


  307. GAUZZI MC
    Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
    Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
    PubMed     Abstract available


  308. SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
    Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
    PubMed     Abstract available


  309. VISWANATHAN S, Wah LM
    A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
    Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
    PubMed     Abstract available


  310. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
    PubMed     Abstract available


  311. PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
    CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
    PubMed     Abstract available


  312. ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
    Functional and structural plasticity following action observation training in multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
    PubMed     Abstract available


  313. KUSPINAR A, Mayo NE
    Validation of the preference-based multiple sclerosis index.
    Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
    PubMed     Abstract available


  314. TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
    Predicting the profile of increasing disability in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
    PubMed     Abstract available


  315. PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
    Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
    PubMed     Abstract available


  316. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018;24:1264-1265.
    PubMed    


  317. BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
    Neurofilaments and 10-year follow-up in multiple sclerosis.
    Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
    PubMed     Abstract available


    July 2018
  318. YANG R, Dunn JF
    Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
    Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
    PubMed     Abstract available


  319. SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
    Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
    Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
    PubMed     Abstract available


  320. HYUN JW, Kim W, Huh SY, Park MS, et al
    Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
    PubMed     Abstract available


  321. HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
    Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
    PubMed     Abstract available


  322. COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
    Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
    PubMed     Abstract available


  323. LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
    Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
    Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
    PubMed     Abstract available


  324. SENDERS A, Hanes D, Bourdette D, Carson K, et al
    Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
    Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
    PubMed     Abstract available


  325. FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
    Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
    PubMed     Abstract available


  326. OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
    Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
    PubMed     Abstract available


  327. WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
    Five years before multiple sclerosis onset: Phenotyping the prodrome.
    Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
    PubMed     Abstract available


  328. WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
    T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
    Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
    PubMed     Abstract available


  329. KEARNEY H
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
    Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
    PubMed    


  330. SASTRE-GARRIGA J
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
    Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
    PubMed    


  331. CORTESE R, Ciccarelli O
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
    Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
    PubMed    


    June 2018
  332. MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
    Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
    Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
    PubMed     Abstract available


  333. PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
    Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
    Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
    PubMed     Abstract available


  334. AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
    New onset seizures as a sole clinical presentation of multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
    PubMed     Abstract available


  335. REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
    Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
    PubMed     Abstract available


  336. CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
    Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
    PubMed     Abstract available


  337. MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
    Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
    PubMed     Abstract available


  338. GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
    Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
    Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
    PubMed     Abstract available


  339. MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
    A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
    Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
    PubMed     Abstract available


  340. ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
    Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
    Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
    PubMed     Abstract available


    May 2018
  341. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed    


  342. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Abstract available


  343. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Abstract available


  344. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Abstract available


  345. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Abstract available


  346. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Abstract available


  347. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Abstract available


  348. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Abstract available


  349. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed    


  350. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Abstract available


  351. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Abstract available


  352. MARANZANO J, Till C, Assemlal HE, Fonov V, et al
    Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
    Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
    PubMed     Abstract available


  353. BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
    alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
    PubMed     Abstract available


    April 2018
  354. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Abstract available


  355. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Abstract available


  356. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Abstract available


  357. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Abstract available


  358. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Abstract available


  359. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed    


  360. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Abstract available


  361. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Abstract available


  362. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Abstract available


  363. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Abstract available


  364. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Abstract available


  365. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Abstract available


  366. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Abstract available


  367. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Abstract available


  368. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed    


  369. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Abstract available


    March 2018
  370. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Abstract available


  371. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Abstract available


  372. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed    


  373. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Abstract available


  374. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Abstract available


  375. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed    


  376. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Abstract available


  377. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Abstract available


  378. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Abstract available


  379. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed    


  380. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Abstract available


  381. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Abstract available


  382. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Abstract available


  383. KIRA JI
    Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold.
    Mult Scler. 2018;24:366-367.
    PubMed    


  384. YAMOUT BI, Zeineddine MM
    Letter to the editor.
    Mult Scler. 2018;24:363.
    PubMed    


  385. PITAROKOILI K, Gold R
    Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder.
    Mult Scler. 2018;24:364-365.
    PubMed    


    February 2018
  386. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Abstract available


  387. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed    


  388. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Abstract available


  389. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Abstract available


  390. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Abstract available


  391. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed    


  392. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed    


  393. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed    


  394. BARKHOF F
    The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
    Mult Scler. 2018;24:125-126.
    PubMed    


  395. PORTER B
    Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
    Mult Scler. 2018;24:233-235.
    PubMed    


    January 2018
  396. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Abstract available


  397. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Abstract available


  398. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed    


  399. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Abstract available


  400. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed    


  401. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed    


  402. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Abstract available


  403. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Abstract available


  404. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Abstract available


  405. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Abstract available


  406. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Abstract available


  407. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Abstract available


  408. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Abstract available


  409. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Abstract available


  410. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Abstract available


  411. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Abstract available


  412. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Abstract available


  413. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Abstract available


  414. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Abstract available


  415. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Abstract available


  416. BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
    Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
    PubMed     Abstract available


  417. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Abstract available


  418. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Abstract available


  419. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed    


  420. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Abstract available


  421. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Abstract available


  422. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Abstract available


  423. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Abstract available


    December 2017
  424. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Abstract available


  425. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Abstract available


  426. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Abstract available


  427. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Abstract available


    November 2017
  428. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Abstract available


  429. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Abstract available


  430. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Abstract available


  431. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Abstract available


  432. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Abstract available


  433. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Abstract available


  434. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Abstract available


  435. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Abstract available


  436. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Abstract available


  437. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Abstract available


  438. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Abstract available


  439. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Abstract available


  440. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Abstract available


  441. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Abstract available


    October 2017
  442. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed    


  443. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed    


  444. BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
    Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
    PubMed     Abstract available


  445. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Abstract available


  446. VAN KEMPEN ZL, Rispens T, Killestein J
    Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Oct 1:1352458517734073. doi: 10.1177/1352458517734073.
    PubMed    


  447. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Abstract available


  448. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed    


  449. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Abstract available


  450. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Abstract available


  451. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Abstract available


  452. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Abstract available


  453. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Abstract available


  454. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Abstract available


  455. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Abstract available


  456. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Abstract available


  457. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Abstract available


    September 2017
  458. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Abstract available


  459. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Abstract available


  460. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Abstract available


  461. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Abstract available


  462. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Abstract available


  463. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Abstract available


  464. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Abstract available


  465. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Abstract available


  466. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Abstract available


  467. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Abstract available


    August 2017
  468. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  469. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  470. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  471. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  472. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  473. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  474. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  475. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  476. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  477. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  478. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  479. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  480. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  481. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  482. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  483. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  484. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  485. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Abstract available


  486. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Abstract available


  487. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Abstract available


  488. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Abstract available


  489. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Abstract available


  490. SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
    Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
    PubMed    


  491. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Abstract available


  492. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Abstract available


  493. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Abstract available


  494. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Abstract available


  495. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Abstract available


  496. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Abstract available


  497. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Abstract available


  498. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Abstract available


  499. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Abstract available


  500. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Abstract available


    July 2017
  501. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Abstract available


  502. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Abstract available


  503. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed    


  504. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Abstract available


  505. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Abstract available


  506. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Abstract available


  507. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Abstract available


  508. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Abstract available


  509. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Abstract available


    June 2017
  510. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Abstract available


  511. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Abstract available


  512. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Abstract available


  513. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Abstract available


  514. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Abstract available


  515. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed    


  516. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Abstract available


  517. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Abstract available


  518. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Abstract available


  519. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed    


  520. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed    


  521. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Abstract available


  522. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Abstract available


  523. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Abstract available


  524. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Abstract available


    May 2017
  525. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Abstract available


  526. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Abstract available


  527. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Abstract available


  528. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Abstract available


  529. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Abstract available


  530. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Abstract available


  531. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Abstract available


  532. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Abstract available


  533. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Abstract available


  534. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Abstract available


  535. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Abstract available


  536. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Abstract available


  537. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Abstract available


  538. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Abstract available


  539. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Abstract available


  540. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Abstract available


  541. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Abstract available


  542. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Abstract available


  543. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Abstract available


  544. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Abstract available


  545. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Abstract available


  546. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Abstract available


  547. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Abstract available


  548. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Abstract available


  549. NETRAVATHI M, Saini J, Mahadevan A, Hari-Krishna B, et al
    Is pruritus an indicator of aquaporin-positive neuromyelitis optica?
    Mult Scler. 2017;23:810-817.
    PubMed     Abstract available


  550. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Abstract available


    April 2017
  551. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Abstract available


  552. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Abstract available


  553. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Abstract available


  554. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Abstract available


  555. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Abstract available


  556. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Abstract available


  557. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Abstract available


  558. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Abstract available


  559. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Abstract available


  560. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Abstract available


  561. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Abstract available


  562. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Abstract available


  563. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Abstract available


  564. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Abstract available


  565. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed    


  566. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Abstract available


  567. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Abstract available


  568. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Abstract available


  569. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Abstract available


  570. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Abstract available


  571. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Abstract available


  572. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Abstract available


  573. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Abstract available


  574. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Abstract available


  575. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Abstract available


  576. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Abstract available


  577. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed    


    March 2017
  578. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Abstract available


  579. ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
    Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
    PubMed     Abstract available


  580. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Abstract available


  581. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Abstract available


  582. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Abstract available


  583. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed    


  584. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed    


  585. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Abstract available


  586. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Abstract available


  587. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Abstract available


  588. HUH SY, Kim SH, Hyun JW, Jeong IH, et al
    Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
    Mult Scler. 2017;23:413-419.
    PubMed     Abstract available


  589. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Abstract available


  590. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed    


  591. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Abstract available


  592. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Abstract available


  593. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Abstract available


  594. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Abstract available


  595. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Abstract available


  596. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Abstract available


    February 2017
  597. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Abstract available


  598. HAMID SH, Elsone L, Mutch K, Solomon T, et al
    The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Mult Scler. 2017;23:228-233.
    PubMed     Abstract available


  599. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Abstract available


  600. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Abstract available


  601. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed    


  602. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed    


  603. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed    


  604. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Abstract available


  605. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Abstract available


  606. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Abstract available


  607. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Abstract available


  608. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Abstract available


  609. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Abstract available


  610. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Abstract available


  611. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Abstract available


  612. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Abstract available


  613. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Abstract available


  614. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Abstract available


    January 2017
  615. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Abstract available


  616. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Abstract available


  617. GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
    Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
    Mult Scler. 2017;23:119-122.
    PubMed     Abstract available


  618. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Abstract available


  619. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Abstract available


  620. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Abstract available


  621. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Abstract available


  622. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Abstract available


  623. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Abstract available


  624. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Abstract available


    December 2016
  625. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed    


    September 2016
  626. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed    


    October 2015
  627. WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
    Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Mult Scler. 2015 Oct 29. pii: 1352458515614092.
    PubMed     Abstract available


  628. UDDIN MN, Lebel RM, Seres P, Blevins G, et al
    Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Mult Scler. 2015 Oct 26. pii: 1352458515614091.
    PubMed     Abstract available


  629. AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
    Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Oct 22. pii: 1352458515613641.
    PubMed     Abstract available


  630. ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
    Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
    Mult Scler. 2015 Oct 22. pii: 1352458515614407.
    PubMed     Abstract available


  631. HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
    Prevalence of neuropathic pain in early multiple sclerosis.
    Mult Scler. 2015 Oct 19. pii: 1352458515613643.
    PubMed     Abstract available


  632. LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
    No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Mult Scler. 2015 Oct 14. pii: 1352458515611222.
    PubMed     Abstract available


  633. KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
    The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
    Mult Scler. 2015 Oct 14. pii: 1352458515610208.
    PubMed     Abstract available


  634. SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
    Vitamin D and axonal injury in multiple sclerosis.
    Mult Scler. 2015 Oct 13. pii: 1352458515606986.
    PubMed     Abstract available


  635. ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
    Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515599246.
    PubMed     Abstract available


  636. HEDSTROM AK, Olsson T, Alfredsson L
    Smoking is a major preventable risk factor for multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515609794.
    PubMed     Abstract available


  637. LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
    Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Mult Scler. 2015 Oct 12. pii: 1352458515608961.
    PubMed     Abstract available


  638. AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
    Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
    Mult Scler. 2015 Oct 9. pii: 1352458515608960.
    PubMed     Abstract available


  639. SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
    Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515604381.
    PubMed     Abstract available


  640. EISELE P, Konstandin S, Griebe M, Szabo K, et al
    Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
    Mult Scler. 2015 Oct 9. pii: 1352458515609430.
    PubMed     Abstract available


  641. RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
    Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
    Mult Scler. 2015 Oct 9. pii: 1352458515606987.
    PubMed     Abstract available


  642. DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
    Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515609795.
    PubMed     Abstract available


  643. MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
    Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Mult Scler. 2015 Oct 7. pii: 1352458515606809.
    PubMed     Abstract available


  644. BOVE R, Healy BC, Musallam A, Glanz BI, et al
    Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Mult Scler. 2015 Oct 7. pii: 1352458515606211.
    PubMed     Abstract available


  645. VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
    Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515610646.
    PubMed     Abstract available


  646. TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
    Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Mult Scler. 2015 Oct 2. pii: 1352458515607650.
    PubMed     Abstract available


  647. RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
    Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515605908.
    PubMed     Abstract available


  648. KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
    Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515604905.
    PubMed     Abstract available


    September 2015
  649. GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
    Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Mult Scler. 2015 Sep 11. pii: 1352458515600247.
    PubMed     Abstract available


  650. MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
    Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515601215.
    PubMed     Abstract available


  651. UHER T, Horakova D, Tyblova M, Zeman D, et al
    Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Mult Scler. 2015 Sep 11. pii: 1352458515601903.
    PubMed     Abstract available


  652. BINZER S, Stenager E, Binzer M, Kyvik KO, et al
    Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
    Mult Scler. 2015 Sep 11. pii: 1352458515602338.
    PubMed     Abstract available


  653. SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
    Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515604384.
    PubMed     Abstract available


    August 2015
  654. GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
    Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Mult Scler. 2015 Aug 18. pii: 1352458515601902.
    PubMed     Abstract available


  655. BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
    Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
    Mult Scler. 2015 Aug 18. pii: 1352458515600248.
    PubMed     Abstract available


  656. TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
    Facial synkinesis as a first symptom of multiple sclerosis.
    Mult Scler. 2015 Aug 5. pii: 1352458515584415.
    PubMed     Abstract available


  657. MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
    Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599450.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: